Your success is our success.
AMRI is a global contract research and manufacturing organization with over twenty years experience providing customers fully integrated lead discovery, process development and API and drug product manufacturing services.
AMRI is a global contract research and manufacturing organization with over twenty years experience providing customers fully integrated lead discovery, process development and API and drug product manufacturing services. The company has steadily expanded, with more than 1400 employees located in facilities throughout the U.S., Europe and Asia.
Since 1991, AMRI has steadily expanded and globalized its contract services platform beyond its major U.S. facilities through a combination of acquisitions and green field initiatives which include:
- process development and large scale manufacturing in the UK;
- medicinal chemistry and custom synthesis in Hungary;
- chemical development and cGMP scale up and manufacturing in India;
- medicinal chemistry and in vitro biology in Singapore;
- aseptic fill and finish capabilities in Burlington, Massachusetts.
AMRI provides a broad range of services and technologies to provide flexible and strategic support for discovery and development of pharmaceutical products and the manufacturing of API and drug product for existing and experimental new drugs, providing geographic proximity and creative budgetary solutions.
Learn more, or schedule a meeting with us at CPhI this month in Frankfurt, Germany (Booth #42f40).
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
